Dr. Ted Love is president and chief executive officer of Global Blood Therapeutics (GBT), a biopharma company that dedicates its time and resources to providing life-changing therapies to underserved communities—specifically, those with sickle cell disease, which disproportionately affects Black people. He received his bachelor’s degree in Molecular Biology from Haverford College, and his medical degree from Yale Medical School.
Under his leadership, GBT has developed the first FDA-approved drug targeting “the underlying causes of sickle cell disease,” Oxbryta.
Sickle cell disease affects approximately 100,000 Americans, the majority of which are of African descent. Those with this disease have sickle (long, slender)-shaped blood cells instead of the traditional round, elastic ones. This can cause blockages in blood vessels and can affect oxygen and blood flow. To learn more about Oxbryta, GBT, and sickle cell disease, read here.